<DOC>
	<DOCNO>NCT00005037</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness temozolomide treat patient stage IIIB , stage IV , recurrent non-small cell lung cancer .</brief_summary>
	<brief_title>Temozolomide Treating Patients With Stage IIIB , Stage IV , Recurrent Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate temozolomide previously treat ( closed accrual 8/01 ) chemotherapy-naive patient advance non-small cell lung cancer . II . Determine freedom progression median , 1-year 2-year survival rate patient regimen . OUTLINE : Patients stratify prior chemotherapy ( yes ( closed accrual 8/01 ) v ) . Patients receive oral temozolomide daily 42 day . Treatment repeat every 8 week 2 year absence disease progression unacceptable toxicity . Patients follow every 2 month . PROJECTED ACCRUAL : Up 66 patient ( 33 per stratum ( previously treat stratum close accrual 8/01 ) ) accrue study within 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Stage IIIB , IV , recurrent nonsmall cell lung cancer curative therapy surgery , radiation , combination chemoradiotherapy exist Chemotherapynaive patient : No prior chemotherapy OR At least 6 month since prior adjuvant , induction , radiosensitizing chemotherapy OR Previously treat patient ( close accrual 8/01 ) : No one prior chemotherapy regimen relapse metastatic disease AND/OR No one prior adjuvant , induction , radiosensitizing chemotherapy within past 6 month Measurable evaluable disease CNS metastases allow ( previously treat metastasis site measurable disease ) No brain metastases prior whole body irradiation PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study No active invasive malignancy PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biologic therapy allow Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Recovered prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>